Trials / Completed
CompletedNCT01642602
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to assess the safety and effectiveness of once daily oral administration of dexlansoprazole delayed-release capsules in adolescent participants with symptomatic non-erosive gastroesophageal reflux disease (GERD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexlansoprazole | Dexlansoprazole delayed-release capsules. |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2012-07-17
- Last updated
- 2014-08-06
- Results posted
- 2014-08-06
Locations
64 sites across 8 countries: United States, Belgium, Brazil, Hungary, Italy, Mexico, Poland, Portugal
Source: ClinicalTrials.gov record NCT01642602. Inclusion in this directory is not an endorsement.